Full Judgment Text
Text read from the judgment PDF published on the High Court's eCourts portal, through the
Indian High Court Judgments open data set (Dattam Labs,
CC BY 4.0).
The court's own copy is the authoritative text.
*
IN THE HIGH COURT OF DELHI AT NEW DELHI
%
Judgment reserved on: 15.01.2026
Judgment delivered on: 23.01.2026
CS(COMM) 1075/2018, I.A. 10890/2018, I.A. 15200/2018, I.A.
11751/2022 & I.A. 188/2025
MERCK SHARP & DOHME CORP. & ANR.
.....Plaintiffs
versus
RANVIR KUMAR BINDESHWARI SINGH & ORS.
....Defendants
Advocates who appeared in this case:
For the Plaintiffs :
Mr. Pravin Anand, Ms. Tusha Malhotra and Ms.
Sugandha Yadav, Advocates.
For the Defendants :
None.
CORAM:
HON'BLE MR. JUSTICE TUSHAR RAO GEDELA
JUDGMENT
TUSHAR RAO GEDELA, J.
1.
The present suit has been filed seeking a decree of permanent
injunction to restrain the defendants from infringement of registered Patent
no.209816, damages, rendition of accounts, delivery up and costs.
2.
The facts as stated in the plaint are that Plaintiff no.1, Merck Sharp &
Dohme Corp., is the owner of the Indian Patent No.209816 (hereinafter
referred to as ‘the suit patent’) that covers, amongst other molecules, a
molecule
having
an
International
Non-Proprietary
Name
(INN),
SITAGLIPTIN, which has the following chemical structure:Signature Not Verified
Digitally Signed
By:YASHRAJ
16:31:34
3.
It is stated that the said molecule was invented by the plaintiff no.1,
which holds patents for the same in 102 countries worldwide and
commercially sells the same in India under the brand/commercial name
JANUVIA. It is also stated in the plaint that the plaintiff no.1 manufactures
another product which is a combination of SITAGLIPTIN and another drug
known as METFORMIN HCI which falls under the protection afforded to
the suit patent. It is stated that the said combination is sold by plaintiff no.1
under the brand/commercial name JANUMET. The plaintiff also sells its
invention under the brand name ISTAVEL and ISTAMET.
4.
The plaintiff no.2, Sun Pharmaceutical Industries Ltd., is the licensee
of plaintiff no.1 for marketing, distributing and selling SITAGLIPTIN and
SITAGLIPTIN & METAFORMIN combination covered and claimed under
the suit patent in India under the trademarks ISTAVEL® and ISTAMET
and also the licensee of the plaintiff no.1 for the suit patent.
5.
As per the plaint, the cause of action arose towards the end of May,
2018 when the plaintiffs learnt about the defendants’ listing of infringing
product ‘SEPAMET-XR’ on www.1mg.com. It is claimed that on
investigation, the advertisements of the defendants’ product containing the
Digitally Signed
By:YASHRAJ
16:31:34
suit patent were also found on several other third party websites such as
www.mednear.com and www.mims.com.
6.
It is stated that the investigator of the plaintiffs had placed orders for
the defendants’ product on various websites, however, the order was
cancelled on every occasion. The investigator had also contacted the
number available on the defendants’ website and spoke to Mr. Pravin, who
revealed that 90% of the defendant no.5’s products are exported and
confirmed that SITAGLIPTIN is only exported and is not available in the
domestic market. It is stated that thereafter, the plaintiffs learnt about the
defendants’ commercial export of the infringing product SEPAMET-XR
through data received from Seair Exim Solutions. Aggrieved thereof, the
present suit was filed in August, 2018.
7.
This Court had granted ex-parte ad interim injunction vide order
dated 16.08.2018 in favour of the plaintiffs, restraining the defendants from
manufacturing, using, selling, distributing, advertising, exporting, offering
for sale and in any other manner, directly or indirectly, dealing in any
product that infringes the suit patent of the plaintiffs or any of the claims
thereof, including SITAGLIPTIN or any of its pharmaceutically acceptable
salts such as Sitagliptin Phosphate Monohydrate as well as any Sitagliptin
containing products.
8.
On 01.10.2018, the defendants entered appearance and were directed
to file their Written Statement. On 09.01.2019, defendant nos.5 & 6 moved
an application bearing I.A. No.143/2019 seeking condonation of delay in
filing their Written Statement, which was allowed subject to costs of
Rs.5000/-.
Digitally Signed
By:YASHRAJ
16:31:34
9.
The defense set up by the defendants is that the defendants are not
exporting any infringing product and do not intend to domestically launch
the infringing product across the country. It has also been stated that the
defendants are not responsible for listings of third party e-commerce
websites and that any incorrect information being displayed on such
websites cannot be attributed to the defendants. The defendants further
denied that SITAGLIPTIN or its various stereo-isomeric forms are covered
by the claims of suit patent of the plaintiffs, and that the plaintiffs have an
exclusive right to prevent the infringement of the said suit patent. It has
further been claimed that even if the defendants are exporting the infringing
products outside India, the same does not give rise to any cause of action to
file a suit before this Court. Further, it is claimed that the defendant nos.5 &
6 being based in Mumbai, manufacturing in Gujarat and having no branch,
warehouse, manufacturing facility or any kind of business activity at all in
Delhi, this Court lacks territorial jurisdiction to entertain the present suit.
10.
On 16.07.2019, the learned counsel who was then appearing for the
defendants, on instructions, stated that it is the stand of the defendants that
they are not manufacturing the drug, SEPAMET-XR 50/500 mg, however,
upon plaintiffs seeking an injunction order, learned counsel sought further
time for instructions. Thereafter, on 02.02.2019, the counsel for defendants
had stated that he intended to move an application seeking discharge. On
28.11.2022, the application moved by the counsel for the defendants
seeking discharge from the matter on account of having not received
instructions from the defendants, was allowed.
11.
On 11.11.2023, the defendant nos.1 to 6 were served through
substituted service by way of publication. Thereafter, on 12.12.2024, as
Digitally Signed
By:YASHRAJ
16:31:34
neither any of the defendants had appeared nor the Written Statement was
filed, the Court had closed the right of the defendants to file Written
Statement.
12.
On 07.03.2024, the Court, while observing that none had been
appearing on behalf of the defendants despite Court notice and substituted
service carried out through publication, proceeded the defendants ex-parte.
On the same day, the plaintiffs had informed the Court that the suit patent
has since lapsed on 05.07.2022 and therefore, any injunction orders will be
infructuous. Thus, the relief in the suit was restricted to costs and damages
against the defendants and accordingly, the plaintiffs were directed to file
an affidavit of evidence relating to costs and damages.
13.
As directed, the plaintiffs filed the affidavit of evidence of PW-1,
Yashodhara Ghorpade. On 05.07.2024, the plaintiffs stated that there is no
need for examination of PW-1 since the plaintiffs are only pressing for
limited relief of damages, in view of the judgement dated 20.10.2023
delivered by this Court in Puma SE vs. Ashok Kumar, CS(COMM)
703/2022.
14.
Since Mr. Pravin Anand, learned counsel for the plaintiff had made a
statement that the subject patent had lapsed on 05.07.2022, the only relief
remaining for the plaintiffs to seek is costs and damages thus, this Court is
restricting its judgment only qua the said relief.
15.
It is a matter of record that though a Written Statement was filed on
behalf of defendant nos.5 & 6 and a replication thereto was also filed by the
plaintiffs (but with delay), however, the defendant nos.1 to 6, out of whom
defendant nos.1 to 4 were/are the Directors of defendant no.5, were
proceeded ex-parte on 07.03.2024. Neither was any application seeking
Digitally Signed
By:YASHRAJ
16:31:34
recall of the order dated 07.03.2024 proceeding the defendant nos.1 to 6 exparte, filed by any of the defendants, nor had any of such defendants even
otherwise appeared before the Court after they were proceeded ex-parte on
07.03.2024.
16.
Since the defendants had neither appeared after 07.03.2024 nor did
they participate in the suit proceedings, the defense raised in the written
statement not having been proved and established by leading evidence, it
would not be possible for this Court to consider any of such defenses on
behalf of the defendants.
17.
On behalf of the plaintiffs, the affidavit of evidence of Ms.
Yashodhara Ghorpade, as PW-1 was filed wherein the witness has
generally deposed in support of the pleadings in the plaint and stated that
plaintiff no.1 is a leading pharmaceutical company dedicated to
discovering, developing and providing pharmaceutical products that
prevent and cure diseases worldwide. Plaintiff no.2 is stated to be a licensee
of plaintiff no.1 for marketing, distributing and selling SITAGLIPTIN
products in India. PW-1 asserts that the defendants were found to be
advertising and selling infringing SITAGLIPTIN tablets under the brand
name ‘SEPAMET-XR’ on third party e-commerce websites like
www.1mg.com, www.mednear.com and www.mims.com. Subsequent data
search of import and export of SITAGLIPTIN drug tablets under the brand
name ‘SEPAMET-XR’ revealed that the same had been exported by
defendant no.5 on multiple occasions.
18.
PW-1 further deposed in the affidavit that one of the methods for
computation of damages to compensate the plaintiffs can be by taking into
consideration the value of illegal profits earned by the defendants in the
Digitally Signed
By:YASHRAJ
16:31:34
course of their infringing activities. She further deposed that the exports by
the defendants from September, 2017 to November, 2017 were obtained
from one Seair Exim Solutions which prepares trade data for different
countries across the globe. The data received from Seair Exim Solutions,
alongwith the copy of e-mail, is extracted hereunder:-
Digitally Signed
By:YASHRAJ
16:31:34
19.
The chart indicating the exports and their value in Indian rupees has
been exhibited as Ex.PW1/2 and is made a part of the affidavit, which is
reproduced hereunder:-
20.
The witness also estimated the period of infringement from
September, 2017 till the date of grant of injunction in the month of August,
2018, which would be a period of 12 months. Reckoning the exports for a
period of three months from September, 2017 to November, 2017 and the
period of infringement, if considered to be 12 months, the approximate
sales made by the defendants at the exchange rate on the date of export, if
taken
into
consideration,
would
be
assessed
approximately
at
Rs.1,97,77,800/-. The witness also stated that if a profit margin of 25% is
assumed, the same would be well over Rs.49,44,450/-. The witness relied
Digitally Signed
By:YASHRAJ
16:31:34
upon an Article titled “Follow the money: the flow of funds in the
pharmaceutical system” by Leonard D. Schaeffer Centre for Health Policy
and Economics which is stated to be exhibited as Ex.PW-1/3 wherein the
statistical estimation that generic manufacturers typically enjoy has been
estimated to be atleast 50% profit margin of the illegal sales made by them.
The witness further stated that in the present case, the plaintiffs are
restricting their claim only to 25% as a conservative estimate.
21.
The witness also asserted and deposed that the plaintiffs are also
entitled to, apart from compensatory damages, an award of punitive and
exemplary damages. In support of the deposition, the witness has also
exhibited as Ex.PW-1/4, the printouts from Wayback Machine which are
stated to be evidence of the defendants advertising the injuncted product for
sale even in 2021. The witness states that the grant of punitive and
exemplary damages may be reckoned following the treble damages rule, in
addition to the actual costs incurred by the plaintiffs. In para 12 of the
affidavit of evidence, the witness has listed out the legal costs as incurred
by the plaintiffs, amounting to Rs.21,67,074/-. Adding the same to the
claim of damages to the extent of Rs.49,44,450/- on account of
compensatory damages, would bring the total to Rs.71,11,524/-.
22.
This Court has heard the arguments of Mr. Pravin Anand, learned
counsel for the plaintiffs and perused the records of the case and proceeds
to consider the merits of the claims.
23.
For the purposes of grant or entitlement of plaintiffs to seek
compensatory damages, it may be worthwhile to take into consideration the
judgment of this Court in Koninlijke Philips & Ors. vs. Amazestore and
Ors.: 2019 SCC OnLine Del 8198, wherein the Court had calculated
Digitally Signed
By:YASHRAJ
16:31:34
damages on the basis of the profits made by the infringers. The relevant
paragraphs of Koninlijke Philips (supra) is extracted hereunder:“26. A Coordinate Bench of this Court in Inter Ikea Systems B.V. v. Sham
Murari, 2018 SCC OnLine Del 11221 has awarded compensatory damages
in favour of the Plaintiffs, after considering the principles enshrined
in Hindustan Unilever (supra) in the following terms:—
“24. In the present case, the Plaintiffs do not claim direct
damages on account of any actual losses suffered by them. The
losses claimed by the Plaintiffs are intangible loss, dilution, loss
of confidence and trust of customers and exemplary damages
due to disregard of the principle of fair trading. Under
Section 73 of the Indian Contract Act, 1872, damages can be
both direct and indirect. However, the nature of damages
claimed in the present case, are for violation of trademark
rights. While this Court does not wish to encourage any party,
which misleads the trademark authorities, the question is
whether a false affidavit filed before the trademark office can by
itself form the basis of grant of exemplary damages. The
documents placed on record point to the fact that the
Defendants had actually registered the domain name
www.ikeaindustries.com only on 7th May, 2014. The Defendant
No. 3 firm was formed on 2nd May, 2014 and the VAT
registration was obtained on 11th September, 2014. Clearly, the
user claimed by the Plaintiffs in its trademark application filed
by Defendant No. 4, Shilpa Metal Industries was completely
incorrect. Thus as on the date when the ex-parte injunction was
granted, i.e., 22nd December, 2014, the Defendants may have
merely used the mark for a few months. Thus, on the basis of the
inventory prepared by the Local Commissioner, which
according to the Plaintiffs is worth Rs. 67,44,800/- and
according to the Defendants is worth approximately Rs.
25,00,000/-, the Court takes the value of the said products to be
in the range of Rs. 25 lakhs to Rs. 30 lakhs, as the said products
were not sold. Even treating the said stock to be the stock of one
month, the total turnover of the Defendants for three months
from September to December 2014, could not have been more
than Rs. 1 crore. This is a rough and ready estimate on the basis
of the seizure made. Since the Defendants would have had to sell
these products with proper dealer/retailer margins, the profit is
estimated at 15% of the total value of the products, which comes
to about Rs. 15 lakhs. In view of the tests laid down in Rookes
Digitally Signed
By:YASHRAJ
16:31:34
and Cassell, the present is not a case for award of punitive
damages.
25. The Defendants' conduct has been far from bonafide. The
manner in which misleading statements have been made and a
false affidavit has been filed before the trademark registry also
calls for the award of exemplary costs, as the trademark
authority is a quasi-judicial authority and any party filing an
affidavit before the said authority should do so with a complete
sense of responsibility. Under the Commercial Courts,
Commercial Division and Commercial Appellate Division of
High Courts Act, 2015 read with the Delhi High Court (Original
Side) Rules, 2018, actual costs can be awarded to the party. The
cost sheet has been placed on record by the Plaintiff. This Court
is of the opinion that costs of Rs. 10 lakhs are liable to be
imposed upon the Defendants. Half of the said sum would be
paid to the Plaintiff and the other half shall be deposited in
favour of the ‘Controller General of Patents, Designs and Trade
marks'. The amount of Rs. 5 lakhs shall be retained in a fund by
the Controller General and shall be utilised for providing legal
assistance for those trade mark applicants and patent applicants
who require legal aid or assistance for paying official fees or
other fees.
26. The suit is thus decreed for damages of Rs. 15,00,000/- and
costs of Rs. 10,00,000/-. Out of the cost of Rs. 10,00,000/-, Rs.
5,00,000/- would be payable to the Plaintiffs. Remaining amount
of Rs. 5,00,000/- shall be deposited with the Controller General
of Patents, Designs and Trademarks. Thus the Plaintiffs are
entitled to a sum of Rs. 20,00,000/- towards general damages
and costs.”
27. This Court is satisfied with the evidence led by the Plaintiffs and the
arguments advanced by the learned counsel for the Plaintiffs that a
conservative margin of profit of 20% can be assumed in the present suits
while assessing the actual damages payable by the Defendants.
28. As regards the compensatory damages payable qua piracy of registered
design, though Mr. Anand submitted that they should be computed after
making some realistic assumptions, this Court is of the view that as the
compensatory damages payable in relation to violation of trade-dress and
copyright have already been computed by the Plaintiffs, it is not necessary
to go into a separate computation of damages for the violation of rights
vested in the Plaintiffs' registered design.
29. As the Defendants have wilfully and repeatedly infringed the Plaintiffs'
rights as vested in their copyright, trade dress and design, the Plaintiffs are
Digitally Signed
By:YASHRAJ
16:31:34
entitled to an award of compensatory damages to the extent of Rs.
69,96,000/- payable by M/s. Omni Exim Private Limited and Rs.
1,45,75,000/- which is to be paid jointly and severally by M/s. Nova
Manufacturing Industries Limited (NOVA) and M/s. Badri Electro Supply
and Trading Company (BESTCO) LLC.”
24.
The plaintiffs also relied upon Rule 20(ii) of the Delhi High Court
Intellectual Property Rights Division Rules, 2022 (IPD Rules) in support of
the prayer for award of compensatory damages, which is extracted
hereunder:“20. Damages/Account of profits –
A party seeking damages/account of profits, shall give a reasonable
estimate of the amounts claimed and the foundational facts/account
statements in respect thereof along with any evidence, documentary and/or
oral led by the parties to support such a claim. In addition, the Court shall
consider the following factors while determining the quantum of damages:
(i) Lost profits suffered by the injured party;
(ii) Profits earned by the infringing party;
(iii) Quantum of income which the injured party may have earned through
royalties/license fees, had the use of the subject IPR been duly authorized;
(iv) The duration of the infringement;
(v) Degree of intention/neglect underlying the infringement;
(vi) Conduct of the infringing party to mitigate the damages being incurred
by the injured party;
In the computation of damages, the Court may take the assistance of an
expert as provided for under Rule 31 of these Rules.”
[Emphasis supplied]
25.
In support of the aforesaid prayer, the plaintiffs have placed on
record, alongwith documents, the computation of compensatory damages
on the basis of illegal profits earned by the defendants through exports from
September, 2017 to November, 2017. The said table is extracted
hereunder:-
Digitally Signed
By:YASHRAJ
16:31:34
The aforesaid calculations are stated to be on the basis of relevant
information obtained from one Seair Exim Solutions which revealed the
data of the defendants undertaking export of the infringing products for a
period of three months i.e. September, 2017 to November, 2017. Apart
from the above, as the injunction order was passed in the month of August,
2018, the period of infringement has been estimated to be for a period of
one year from September, 2017 to August, 2018. Based thereon, if the
approximate sales for the said period of three months from September,
2017 to November, 2017 are assessed at Rs.49,44,450/-, on a multiplier of 4
(four quarters of a year) for 12 months, the approximate figure for one year
would be Rs.1,97,77,800/-, which remains unchallenged. A 25% profit
margin would approximately be Rs.49,44,450/-. Thus, the plaintiffs are
found entitled to compensatory damages to the extent of Rs.49,44,450/-.
26.
In so far as the relief sought for exemplary damages is concerned, the
plaintiffs have contended that the defendants were well aware of the rights
of the plaintiffs in the subject patent and even after having been injuncted
by this Court vide order dated 16.08.2018, they appear to be willfully
violating the rights of the plaintiffs and disobeying the said injunction
Digitally Signed
By:YASHRAJ
16:31:34
order. This assertion is based on the copies of the advertisement of the
infringing product being offered for sale on e-pharmacies in January, 2021,
April, 2021 as well as August, 2021, which have collectively been marked
and exhibited as Ex.PW-1/4, and extracted hereunder:-
Digitally Signed
By:YASHRAJ
16:31:34
Digitally Signed
By:YASHRAJ
16:31:34
27.
The plaintiffs further assert that the manufacture of the infringing
product SEPAMET-XR led to the infringement of the suit patent which
posed serious public health risks as consumers were at a risk of receiving
sub-standard medicines, believing them to be from the plaintiffs’ qualityassured manufacturing facilities. The plaintiffs have also relied upon a
number of judgments passed by this Court as well as by other High Courts
in support of the relief of exemplary damages. Some of those are Whatman
International Limited vs. Paresh Mehta & Ors.: 2019 SCC OnLine Del
6856, Glenmark Pharmaceuticals vs. Curetech Skincare and Galpha
Laboratories Ltd.: 2018 SCC OnLine Bom 11559 and Blue Heaven
Cosmetics Pvt. Ltd. vs. Shivani Cosmetics: 2022 SCC OnLine Del 1523.
The ratio laid down by the said judgments is in favour of entities such as
the plaintiffs in the present case, for grant of exemplary damages in similar
cases.
28.
Apart from the ratio laid down by the aforesaid judgments, what
propels this Court towards the relief of exemplary damages is the fact that
the defendants had altogether stopped appearing after they were proceeded
ex-parte on 07.03.2024, and since the affidavit of evidence of PW-1 was
neither rebutted nor any counter evidence was produced or placed on record
by the defendants, this Court is inclined to grant exemplary damages to the
tune of Rs.10 Lakhs in favour of the plaintiffs.
29.
So far as the relief of legal costs are concerned, PW-1 in para 12 of
the evidence by way of her affidavit has deposed that the plaintiffs had, (i)
affixed Rs.1,98,000/- towards payment of Court Fees on the suit plaint, (ii)
incurred expenses of Rs.1,20,731.21/- on account of having filed the
present suit and also; (iii) incurred an expense of Rs.18,48,343.30/- on
Digitally Signed
By:YASHRAJ
16:31:34
account of payment of legal fees. All the aforesaid expenses stated to have
been incurred are supported by the affidavit of PW-1, Ms. Yashodhara
Ghorpade. In view of the observations made in para 28 above and no
rebuttal to the said affidavit of PW-1 by the defendants, there is no reason
why this Court should not believe the statement of expenses incurred by the
plaintiffs, therefore, the plaintiffs would be entitled to a total sum of
Rs.21,67,074/- as costs.
30.
Accordingly, the suit is hereby decreed in favour of the plaintiffs and
against the defendants in terms of para 102(b) and 102(d) of the prayer
clause in the plaint. The plaintiffs are entitled to, (i) a sum of
Rs.49,44,450/- as compensatory damages; (ii) a sum of Rs.10,00,000/- as
exemplary damages; and (iii) a sum of Rs.21,67,074/- as costs, to be paid
by the defendants jointly and severally.
31.
Decree sheet be drawn up accordingly.
32.
The present suit, alongwith pending applications, stands disposed of.
TUSHAR RAO GEDELA
(JUDGE)
JANUARY 23, 2026/kct/rl
Digitally Signed
By:YASHRAJ
16:31:34
This page is for informational and research purposes only and does not constitute legal advice.
Consult a qualified advocate for advice specific to your situation.
Is your name in this judgment and should it be masked, or is something on this page wrong?
Request a review